An Oxford-led trial found adalimumab nearly halved uveitis relapses, even in patients NICE rules exclude. The team wants NICE to widen access to the drug.
A trial co-led by doctors at the Oxford Eye Hospital has found that the drug adalimumab protects the sight of many more people with the eye condition uveitis than NHS funding rules currently allow. Around 85% of the patients in the ASTUTE trial would not have qualified for the drug under the rules the National Institute for Health and Care Excellence (NICE) set in 2017. The team has put its findings to NICE. (Oxford University Hospitals, 12 November 2026)
Overview
- The result: a year on, 31.4% of patients who stayed on adalimumab relapsed or needed more treatment, against 59% of those switched to a dummy injection.
- The patients NICE excludes: for them, staying on the drug cut the risk of treatment failure by 63%.
- The cost: £662 extra per patient per year, or £2,320 to prevent one episode of treatment failure.
- What happens next: the research team has asked NICE to widen who is eligible.
What uveitis is
Uveitis is inflammation inside the eye. The non-infectious form is considered rare, but it is a leading cause of blindness in high-income countries.
Adalimumab is already used in the NHS for arthritis and some forms of eye inflammation. It is the only non-steroid treatment licensed for uveitis. NICE funds it for non-infectious uveitis only for patients who meet a narrow set of conditions, set out in guidance from 2017. That guidance was written before trials in this group of patients had been done.
How the trial worked
ASTUTE was co-led by Oxford University Hospitals (OUH) and Bristol NHS Foundation Trust. It recruited patients with non-infectious uveitis at 18 hospitals across the UK.
- Everyone was given adalimumab for 16 weeks alongside their usual care.
- Patients whose eyes settled then either stayed on the drug or moved to a dummy injection.
- Neither the patients nor their doctors knew which.
A year later, the gap was wide. Side effects were no more common on the drug than on the dummy injection. The findings are published in eClinicalMedicine.
University of Oxford health economists worked out the cost to the NHS. The trial used a cheaper biosimilar version of adalimumab, the kind the NHS routinely uses.
What the doctors say
Dr Srilakshmi Sharma, Consultant Medical Ophthalmologist at the Oxford Eye Hospital, is the trial’s co-chief investigator and senior author. She said:
“We set out to answer a question that patients have been asking us in clinic for years, which is whether this drug would help them if only they were allowed to have it. The answer is yes, for many of them.
“These are people who come to our clinics with their sight at risk, and who we currently have to tell that the funding rules do not cover them. We now have UK trial evidence, from NHS clinics and patients, that the rules are drawn in the wrong place.”
Professor Andrew Dick, of the University of Bristol and University College London, is the other co-chief investigator. He said stopping the drug in people who are doing well on it “leads to relapse in most of them”.
Patients helped design the trial before it opened. Annie Folkard, co-founder of the Birdshot Uveitis Society, which supported it, said more than a hundred people “gave up years of appointments and tests to see it through”.
The study was also funded by the NIHR Health Technology Assessment Programme and the NIHR Biomedical Research Centres at Moorfields and Oxford.
What it means for you
- NICE’s rules have not changed yet. The team has submitted its findings, but until NICE updates its guidance the 2017 eligibility conditions still apply.
- If you have uveitis and have been told you do not qualify, this is a fair question to raise with your eye specialist at your next appointment.
- The NHS explains the condition on its uveitis page, including symptoms that need urgent attention.
Have your say